Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Schoonheim

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
AJNR. American Journal of Neuroradiology|March 12, 2016
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple SclerosisO T Wiebenga, M M Schoonheim, H E Hulst, et al.
Multiple Sclerosis and Related Disorders|December 16, 2018
Acid sphingomyelinase: No potential as a biomarker for multiple sclerosisC E Leurs, M A Lopes Pinheiro, L Wierts, et al.
Multiple Sclerosis and Related Disorders|March 28, 2025
Associations between physical fitness and structural and functional MRI measures in secondary progressive multiple sclerosis: Cross-sectional findings from the exercise PRO-MS studyA S Gravesteijn, A van der Kruit, M Bet, et al.
Neuroimage. Clinical|October 8, 2021
Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain networkJ A Nij Bijvank, E M M Strijbis, I M Nauta, et al.
Journal of Neurology|June 2, 2026
What if it is the eyes? The effect of eye movement disorders on cognitive testing in MSS N Hof, E Keytsman, T A N Fuchs, et al.
Psychiatry Research|February 11, 2024
Dynamic reconfigurations of brain networks in depressive and anxiety disorders: The influence of antidepressantsT A A Broeders, F Linsen, T S Louter, et al.
Journal of Neurology|July 23, 2025
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)W H Fung, M H J Wessels, E M E Coerver, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
AJNR. American Journal of Neuroradiology|March 12, 2016
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple SclerosisO T Wiebenga, M M Schoonheim, H E Hulst, et al.
Multiple Sclerosis and Related Disorders|December 16, 2018
Acid sphingomyelinase: No potential as a biomarker for multiple sclerosisC E Leurs, M A Lopes Pinheiro, L Wierts, et al.
Multiple Sclerosis and Related Disorders|March 28, 2025
Associations between physical fitness and structural and functional MRI measures in secondary progressive multiple sclerosis: Cross-sectional findings from the exercise PRO-MS studyA S Gravesteijn, A van der Kruit, M Bet, et al.
Neuroimage. Clinical|October 8, 2021
Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain networkJ A Nij Bijvank, E M M Strijbis, I M Nauta, et al.
Journal of Neurology|June 2, 2026
What if it is the eyes? The effect of eye movement disorders on cognitive testing in MSS N Hof, E Keytsman, T A N Fuchs, et al.
Psychiatry Research|February 11, 2024
Dynamic reconfigurations of brain networks in depressive and anxiety disorders: The influence of antidepressantsT A A Broeders, F Linsen, T S Louter, et al.
Journal of Neurology|July 23, 2025
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)W H Fung, M H J Wessels, E M E Coerver, et al.
Pageof 3